Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Autologous Anti-CD22 CAR T Cells (CART22-65s) Co-administered With Humanized Anti-CD19 CAR T Cells (huCART19) in Children and Young Adults With Relapsed or Refractory B-ALL

NCT05674175 is registered in ClinicalTrials.gov with Stephan Grupp MD PhD as lead sponsor.

NCT NCT05674175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05674175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Autologous Anti-CD22 CAR T Cells (CART22-65s) Co-administered With Humanized Anti-CD19 CAR T Cells (huCART19) in Children and Young Adults With Relapsed or Refractory B-ALL
Lead sponsor
Stephan Grupp MD PhD
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 25, 2023
Completion date
July 1, 2029
Enrollment
93 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b lineage lymphoblastic lymphoma, b-cell acute lymphoblastic leukemia